Management of erythema nodosum leprosum by thalidomide: Thalidomide analogues inhibit M. leprae-induced TNFα production in vitro

Biomedicine and Pharmacotherapy

Volumn 56, Issue 1, 2002, Pages 13-19

  Sampaio, E P ^a   Hernandez, M O ^a   Carvalho, D S ^a   Sarno, E N ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Analogues; Leprosy; Thalidomide; TNF

Indexed keywords

INTERLEUKIN 12; MESSENGER RNA; N BUTYLPHTHALIMIDE; N HYDROXYPHTHALIMIDE; N METHYLATHYLKETONEPHTHALIMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; CELL CULTURE; CELL STIMULATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MONOCYTE; MYCOBACTERIUM LEPRAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0036175514     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(01)00147-0     Document Type: Article

References (42)

1. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
2. Potential novel uses of Thalidomide
3. Immunology of leprosy: Some aspects of the role of the immune system in the pathogenesis of the disease
4. Role of inflammatory cytokines in tissue injury in leprosy
5. The saga of thalidomide: Neuropathy to embryopathy, with case reports and congenital abnomalities
6. Thalidomide in the treatment of lepra reactions
7. Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes
8. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
9. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species
10. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production
11. Thalidomide on the comeback trail
12. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
13. The role of tumor necrosis factor in health and disease
14. Serum levels of tumor necrosis factor-alpha and interleukin-1β during leprosy reactional states
15. Thalidomide exerts its inhibitory action on TNFα by enhancing mRNA degradation
16. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients
17. Development of giant reaction in response to PPD skin test in lepromatous leprosy patients
18. The influence of thalidomide on the clinical and immmunologic manifestion of erythema nodosum leprosum
19. Is pentoxifylline a viable alternative in the treatment of ENL?
20. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL)
21. Cytokine mRNA expression in leprosy: A possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL)
22. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients
23. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production
24. Selective down-regulation of T cell-derived tumour necrosis factor α by thalidomide: Comparisons with dexamethasone
25. Neutrophils isolated from leprosy patients release TNFα and exhibit accelerated apoptosis in vitro
26. Thalidomide and derivatives: Immunological investigations of tumour necrosis factor-alpha (TNFα) inhibition suggest drugs capable of selective gene regulation
27. Inhibition of interleukin-12 production by thalidomide
28. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
29. Mouth and pharyngeal hyperalgesic syndromes in AIDS
30. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
31. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNFα production
32. Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-alpha production
33. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide analogues
34. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophtalimides
35. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNFα
36. IL-12 regulates T helper type 1 cytokine responses in human infectious disease
37. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptative immunity
38. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions
39. Inhibition of apoptosis by ionomycin and zinc in peripheral blood mononuclear cells (PBMC) of leprosy patients
40. Immunomodulatory assays to study structure-activity relationships of thalidomide
41. Classification of leprosy according to immunity: A five group system
42. Inibition NFκB activity by thalidomide through suppression of IκB kinase activity